| Ms Meghen Anne Clancy, PNP | |
|
Health Care And Rehabilitation Center, 107 Park St, Springfield, VT 05156 | |
| (802) 885-5781 | |
| (802) 885-4857 |
| Full Name | Ms Meghen Anne Clancy |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist - Psychiatric/mental Health |
| Location | Health Care And Rehabilitation Center, Springfield, Vermont |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306911615 | NPI | - | NPPES |
| 1004643 | Medicaid | VT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SP0808X | Clinical Nurse Specialist - Psychiatric/mental Health | 1010014569 (Vermont) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Meghen Anne Clancy, PNP One Hospital Court, Suite 410, Bellows Falls, VT 05101 Ph: (802) 463-3947 | Ms Meghen Anne Clancy, PNP Health Care And Rehabilitation Center, 107 Park St, Springfield, VT 05156 Ph: (802) 885-5781 |
News Archive
Publishing their work in Nature, scientists at the UNC School of Medicine and UNC Gillings School of Global Public Health found that the orally administered experimental drug EIDD-2801 halts SARS-CoV-2 replication and prevents infection of human cells in a new in vivo lab model containing human lung tissue.
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has determined that additional time is required to complete the review of the biologics license application (BLA) for ipilimumab in pre-treated advanced melanoma, and has moved its decision date from December 25, 2010 to March 26, 2011.
MedImmune today announced that it has initiated a Phase 1/2a clinical trial of a live, attenuated intranasal vaccine in healthy children one month to 12 months of age to help prevent severe respiratory syncytial virus (RSV) infections. RSV is the most common respiratory infection in infants and can cause disease in otherwise healthy infants and children.
Results for a pilot registry on the management and treatment of atrial fibrillation in Europe were presented yesterday by the European Society of Cardiology. AF is the commonest cardiac rhythm disorder and each of us have a one-in-four lifetime risk of developing it. Statistics show that oral anticoagulant use has increased, but new oral anticoagulant use is still low. Authors also concluded that compliance with treatment guidelines for patients with the lowest and higher stroke risk scores remains suboptimal.
› Verified 6 days ago